What is DisperSol?
DisperSol operates at the intersection of advanced material science and pharmacology, leveraging its proprietary KinetiSol technology platform to address the critical challenge of poor drug bioavailability. By transforming poorly soluble compounds into highly bioavailable therapeutics, the company provides a vital lifeline for patients where conventional treatment modalities have proven ineffective. The firm's current clinical portfolio is anchored by DST-0509, which is advancing toward Phase 3 trials for iron overload disorder, and DST-2970, currently in Phase 2 development for refractory metastatic prostate cancer. This specialized focus on high-unmet-need indications positions DisperSol as a significant player in the biopharmaceutical sector, capable of bridging the gap between complex molecular discovery and patient-centric clinical outcomes.
How much funding has DisperSol raised?
DisperSol has raised a total of $70.3M across 8 funding rounds:
Unspecified
$641K
Debt
$611K
Private Equity
$3M
Private Equity
$10M
Private Equity
$12M
Private Equity
$16M
Unspecified
$27M
Debt
$1M
Unspecified (2012): $641K, investors not publicly disclosed
Debt (2013): $611K, investors not publicly disclosed
Private Equity (2014): $3M, investors not publicly disclosed
Private Equity (2015): $10M featuring Research
Private Equity (2016): $12M, investors not publicly disclosed
Private Equity (2018): $16M, investors not publicly disclosed
Unspecified (2018): $27M, investors not publicly disclosed
Debt (2020): $1M supported by PPP
Key Investors in DisperSol
Research Corporation Technologies
A specialized firm focused on the development and commercialization of advanced expression technologies, including endotoxin-free protein production systems for pharmaceutical research.
Undisclosed Institutional Investor
An undisclosed investor participating in the funding round, providing strategic capital to support clinical-stage drug development initiatives.
Undisclosed Institutional Investor
An undisclosed investor participating in the funding round, providing strategic capital to support clinical-stage drug development initiatives.
What's next for DisperSol?
The infusion of capital from the latest financing round provides DisperSol with the necessary runway to accelerate its late-stage clinical programs and refine its KinetiSol platform for broader therapeutic applications. As the company transitions toward potential commercialization, the strategic focus will likely shift toward regulatory milestones and the expansion of its early-stage pipeline, including the DST-5407 program for non-small cell lung cancer. By maintaining a disciplined approach to capital allocation and clinical execution, DisperSol is well-positioned to enhance its valuation and solidify its standing as a leader in the development of next-generation pharmaceutical solutions.
See full DisperSol company page
